Novo Nordisk A/S

(NVO) Trade

By |

Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Contact Information

Website: www.novonordisk.com
Email: phak@novonordisk.com
Main Phone: +45 44448888
Address: Novo Alle
City / Town: Bagsværd
Country: DNK
Postal Code: 2880

Issuer Information

Exchange: NYE
CEO: Lars Fruergaard Jorgensen
Employees: 43161
NAICS: Pharmaceutical P
$ 45.52 $ -0.43 (-0.94%)
Last Price 45.52 Change $ -0.43 Change % -0.94 Tick N/A
Bid 45.51 Bid Size 400.00 Ask 45.52 Ask Size 200.00
Open 45.96 High 46.03 Low 45.46 Prev Close 45.95
Last Trade Volume 472,856 52 Wk Hi 58.37 52 Wk Low 41.23
Market Cap 109.1 bi Ex-Div Date Div Rate 0.92 Yield 2.0120
Shares 2,397,028,352.00 EPS (TTM) 2.56 PE Ratio 17.70 Exchange NYSE
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 60.4 60.4 60.4 60.4
Low Target Price Estimate 60.4 60.4 60.4 60.4
Mean Target Price Estimate 60.4 60.4 60.4 60.4
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 05/29/18 05/29/18 05/03/18 05/29/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 1 1 1 1
Hold 2 2 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.13 2.13 2.13 2.3